Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Discontinued Operations (Tables)

v3.10.0.1
Note 3 - Discontinued Operations (Tables)
 9 Months Ended
Sep. 30, 2018
Notes Tables  
Disposal Groups, Including Discontinued Operations [Table Text Block]
   
September
30
,
2018
    
December 31,
2017
  
Accrued liabilities
   $
—
     $
7,092
  
Liabilities associated with discontinued operations, current
   $
—
     $
7,092
  
   
Three Months Ended
September
30,
    
Nine
Months Ended
September
30,
  
   
2018
    
2017
    
2018
    
2017
  
Lymphoseek sales revenue
   $
—
     $
—
     $
—
     $
2,917,213
  
Cost of goods sold
    
—
      
—
      
—
      
364,192
  
Gross profit
    
—
      
—
      
—
      
2,553,021
  
Operating expenses:
                                
Research and development
    
—
      
(5,951
)
    
2,453
      
382,070
  
Selling, general and administrative
    
—
      
—
      
—
      
805,464
  
Total operating expenses
    
—
      
(5,951
)
    
2,453
      
1,187,534
  
(Loss) income from discontinued operations
    
—
      
5,951
      
(2,453
)
    
1,365,487
  
Interest expense
    
—
      
—
      
—
      
(1,718,506
)
(Loss) income before income taxes
    
—
      
5,951
      
(2,453
)
    
(353,019
)
Benefit from (provision for) income taxes
    
—
      
(552
)
    
515
      
20,181
  
(Loss) income from discontinued operations
   $
—
     $
5,399
     $
(1,938
)
   $
(332,838
)